Missions

Aditxt actively evaluates strategic acquisitions that align with its immune health focus, enhance its technology pipeline, and/or provide revenue-generating opportunities.

These acquisitions are part of Aditxt’s broader strategy to expand its portfolio, enhance its technological capabilities, and drive long-term value creation. Updates on these initiatives will be provided as discussions progress.

NASDAQ: ADTX

Aditxt is a social innovation platform accelerating promising innovations with the potential to address some of our most pressing health challenges.

Current Focus Areas (Subsidiaries)

adimune logo

 

Through Adimune™, developing a transformative approach to autoimmunity—focused on restoring immune tolerance rather than suppressing the immune system.

pearsanta logo

Via Pearsanta™, advancing early cancer detection through precision diagnostics — with plans to develop adductomics-based screening to advance towards pre-cancer detection.

Adivue

Through Adivue™, advancing innovative solutions for neurodegenerative and neuroinflammatory conditions.

Planned Expansion Areas (Proposed Acquisitions)

appili therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused. By identifying urgent infections with unmet needs, Appili is developing a pipeline of novel therapies to prevent deaths and improve lives.

evofem biosciences logo

Through Evofem™, addressing critical unmet needs in reproductive and sexual health.

Aditxt Video Library (NASDAQ: ADTX)